Management of Staphylococcus aureus and Coagulase‑Negative Staphylococcal Bacteremia

Empirical Therapy (Before Susceptibility Results)

• Initiate vancomycin 30–60 mg/kg/day intravenously in 2–4 divided doses, targeting trough concentrations of 15–20 µg/mL for serious infections, or daptomycin 6 mg/kg intravenously once daily to provide MRSA coverage while awaiting culture results. 1
• In regions with high MRSA prevalence, empirical MRSA‑active therapy is essential because delays in appropriate treatment worsen clinical outcomes. 2

Definitive Therapy Based on Susceptibility

Methicillin‑Susceptible S. aureus (MSSA)

• Switch immediately to cefazolin or an anti‑staphylococcal penicillin (nafcillin/oxacillin) once MSSA is confirmed. 2
• Beta‑lactam agents are superior to vancomycin for MSSA infections and are associated with lower recurrence rates. 1
• Cefazolin is preferred over anti‑staphylococcal penicillins because it offers a comparable efficacy with a better safety profile, based on large observational studies. 3

Methicillin‑Resistant S. aureus (MRSA)

• Continue vancomycin 30–60 mg/kg/day intravenously (target trough 15–20 µg/mL) or daptomycin 6 mg/kg intravenously once daily for uncomplicated MRSA bacteremia. 3
• For complicated or persistent MRSA bacteremia, consider escalating daptomycin to 8–10 mg/kg intravenously once daily. 4
• In cases of persistent MRSA bacteremia or antibiotic failure, add ceftaroline to daptomycin (combination therapy). 5

Coagulase‑Negative Staphylococci (CoNS)

• Remove the implicated catheter and treat with vancomycin for 5–7 days for uncomplicated catheter‑related bloodstream infection. 6
• True CoNS infection is suggested by multiple positive blood cultures, quantitative catheter cultures ≥100 CFU/mL, or a differential time to positivity >2 hours. 6

Mandatory Source Control

• Remove all infected intravascular catheters and implanted devices immediately. 5
• Drain any abscesses and debride infected tissue as part of definitive management. 1
• Failure to achieve adequate source control is a primary cause of treatment failure. 4

Required Diagnostic Workup

• Obtain follow‑up blood cultures 2–4 days after therapy initiation to document clearance. 5
• Perform transthoracic echocardiography (TTE) on all patients with S. aureus bacteremia. 5
• Proceed directly to transesophageal echocardiography (TEE) for high‑risk patients (persistent bacteremia, fever >72 h, prosthetic valve, injection drug use, or clinical signs of endocarditis). 5
• TEE provides superior sensitivity (32–82 % greater) compared with TTE for detecting vegetations and complications. 4

Treatment Duration

Uncomplicated S. aureus Bacteremia

• Minimum 14 days of therapy if all of the following are met: negative follow‑up cultures within 2–4 days, defervescence within 72 h, no endocarditis on imaging, no prosthetic devices, and no metastatic infection. 1
• Shorter courses are linked to a significantly higher relapse rate. 1

Complicated S. aureus Bacteremia

• Treat for 4–6 weeks when any criterion for uncomplicated infection is not satisfied. 5
• Prolonged bacteremia carries a 39 % 90‑day mortality risk. 1
• Specific complications dictate extended therapy: septic thrombosis or endocarditis – 4–6 weeks; osteomyelitis – 6–8 weeks. 6

Renal Dosing Adjustments

• For creatinine clearance < 30 mL/min, adjust vancomycin dosing based on serum levels; give daptomycin 6 mg/kg every 48 hours for bacteremia. 4

Common Pitfalls to Avoid

• Do not continue vancomycin for MSSA once methicillin susceptibility is confirmed; beta‑lactams yield superior outcomes. 3
• Never treat S. aureus bacteremia without obtaining follow‑up blood cultures; persistent bacteremia markedly increases mortality and necessitates reassessment. 5
• Do not omit echocardiography; detection of endocarditis extends therapy from 14 days to 4–6 weeks. 5
• Catheter removal alone is insufficient; systemic antibiotics remain required after device extraction. 6
• Cefazolin should not be used for MRSA, as it lacks activity against methicillin‑resistant strains. 3

Empiric Management of Coagulase‑Negative Staphylococcus Infections

Clinical Significance and Diagnosis

• Coagulase‑negative staphylococci (CoNS) are generally low‑virulence organisms that seldom cause rapid clinical deterioration; therefore, routine urgent initiation of vancomycin is not required unless specific high‑risk features are present (Infectious Diseases Society of America) 7.
• A solitary positive blood culture for CoNS should be regarded as a contaminant when subsequent cultures remain negative (IDSA) 7.

Indications for Empiric Vancomycin Coverage

• Vancomycin should be added to the empiric regimen in any of the following high‑risk scenarios:

De‑escalation and Discontinuation of Vancomycin

• If CoNS infection is not confirmed by repeat cultures, vancomycin added empirically should be discontinued after 2–3 days of therapy (IDSA) [7][8].

Special Populations

• In patients with cancer‑related neutropenia, vancomycin is not a standard component of empiric therapy for fever and neutropenia; it may be omitted unless high‑risk features are identified (IDSA) 7.

Hospital‑Acquired Infection Threshold

• When the prevalence of methicillin‑resistant Staphylococcus aureus (MRSA) among S. aureus isolates exceeds 20 % in a given institution, empiric vancomycin coverage is recommended for suspected CoNS infection, balancing effective early therapy against the risk of unnecessary broad‑spectrum use (IDSA) 9.